SG178744A1 - Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation - Google Patents

Info

Publication number

SG178744A1

SG178744A1 SG2012007456A SG2012007456A SG178744A1 SG 178744 A1 SG178744 A1 SG 178744A1 SG 2012007456 A SG2012007456 A SG 2012007456A SG 2012007456 A SG2012007456 A SG 2012007456A SG 178744 A1 SG178744 A1 SG 178744A1

Authority

SG

Singapore

Prior art keywords

seq

polypeptide

sema6a

mammal

disease

Prior art date

2007-02-02

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004248 oligodendroglia Anatomy 0.000 title claims abstract description 114
• 230000023105 myelination Effects 0.000 title claims abstract description 33
• 230000001737 promoting effect Effects 0.000 title claims abstract description 24
• 102100032795 Semaphorin-6A Human genes 0.000 title claims abstract description 6
• 101710199479 Semaphorin-6A Proteins 0.000 title claims abstract description 6
• 230000004069 differentiation Effects 0.000 title claims description 36
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 381
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 374
• 229920001184 polypeptide Polymers 0.000 claims abstract description 372
• 238000000034 method Methods 0.000 claims abstract description 179
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 86
• 201000010099 disease Diseases 0.000 claims abstract description 55
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 47
• 230000006378 damage Effects 0.000 claims abstract description 43
• 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 18
• 206010012305 Demyelination Diseases 0.000 claims abstract description 17
• 206010067601 Dysmyelination Diseases 0.000 claims abstract description 12
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 223
• 210000004027 cell Anatomy 0.000 claims description 119
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 74
• 230000014509 gene expression Effects 0.000 claims description 61
• 239000013598 vector Substances 0.000 claims description 60
• 239000000203 mixture Substances 0.000 claims description 54
• 241000124008 Mammalia Species 0.000 claims description 52
• 229920001223 polyethylene glycol Polymers 0.000 claims description 37
• 229920000642 polymer Polymers 0.000 claims description 37
• 239000002202 Polyethylene glycol Substances 0.000 claims description 36
• 239000012634 fragment Substances 0.000 claims description 30
• 208000035475 disorder Diseases 0.000 claims description 29
• 210000002569 neuron Anatomy 0.000 claims description 29
• 208000027418 Wounds and injury Diseases 0.000 claims description 27
• 208000014674 injury Diseases 0.000 claims description 27
• 108091033319 polynucleotide Proteins 0.000 claims description 27
• 102000040430 polynucleotide Human genes 0.000 claims description 27
• 239000002157 polynucleotide Substances 0.000 claims description 27
• 230000003902 lesion Effects 0.000 claims description 21
• 230000004083 survival effect Effects 0.000 claims description 20
• 230000035755 proliferation Effects 0.000 claims description 18
• 208000012902 Nervous system disease Diseases 0.000 claims description 17
• 239000013603 viral vector Substances 0.000 claims description 17
• 239000013604 expression vector Substances 0.000 claims description 15
• 230000008685 targeting Effects 0.000 claims description 13
• 201000002491 encephalomyelitis Diseases 0.000 claims description 12
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 12
• 102000006386 Myelin Proteins Human genes 0.000 claims description 11
• 108010083674 Myelin Proteins Proteins 0.000 claims description 11
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 11
• 230000001684 chronic effect Effects 0.000 claims description 11
• 210000005012 myelin Anatomy 0.000 claims description 11
• 229920001515 polyalkylene glycol Polymers 0.000 claims description 10
• 208000011580 syndromic disease Diseases 0.000 claims description 10
• 238000001802 infusion Methods 0.000 claims description 9
• 230000004770 neurodegeneration Effects 0.000 claims description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 7
• 108060003951 Immunoglobulin Proteins 0.000 claims description 7
• 102000018358 immunoglobulin Human genes 0.000 claims description 7
• 230000001404 mediated effect Effects 0.000 claims description 7
• 208000011403 Alexander disease Diseases 0.000 claims description 6
• 208000018737 Parkinson disease Diseases 0.000 claims description 6
• 238000002512 chemotherapy Methods 0.000 claims description 6
• 230000034994 death Effects 0.000 claims description 6
• 208000024827 Alzheimer disease Diseases 0.000 claims description 5
• 208000006373 Bell palsy Diseases 0.000 claims description 5
• 208000023105 Huntington disease Diseases 0.000 claims description 5
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 5
• 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims description 5
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 5
• 208000003435 Optic Neuritis Diseases 0.000 claims description 5
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 5
• 206010069350 Osmotic demyelination syndrome Diseases 0.000 claims description 5
• 108010071390 Serum Albumin Proteins 0.000 claims description 5
• 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 5
• 206010047631 Vitamin E deficiency Diseases 0.000 claims description 5
• 206010073696 Wallerian degeneration Diseases 0.000 claims description 5
• 230000001154 acute effect Effects 0.000 claims description 5
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 5
• 210000003169 central nervous system Anatomy 0.000 claims description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 5
• 238000002347 injection Methods 0.000 claims description 5
• 239000007924 injection Substances 0.000 claims description 5
• 208000005264 motor neuron disease Diseases 0.000 claims description 5
• 208000020431 spinal cord injury Diseases 0.000 claims description 5
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
• 230000008734 wallerian degeneration Effects 0.000 claims description 5
• 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 4
• 208000001827 Ataxia with vitamin E deficiency Diseases 0.000 claims description 4
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 4
• 208000001738 Nervous System Trauma Diseases 0.000 claims description 4
• 208000019155 Radiation injury Diseases 0.000 claims description 4
• 102000007562 Serum Albumin Human genes 0.000 claims description 4
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
• 235000018417 cysteine Nutrition 0.000 claims description 4
• 201000003264 familial isolated deficiency of vitamin E Diseases 0.000 claims description 4
• 201000010901 lateral sclerosis Diseases 0.000 claims description 4
• 208000028412 nervous system injury Diseases 0.000 claims description 4
• 208000009174 transverse myelitis Diseases 0.000 claims description 4
• 241001529453 unidentified herpesvirus Species 0.000 claims description 4
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 claims description 3
• 241000710929 Alphavirus Species 0.000 claims description 3
• 241000709661 Enterovirus Species 0.000 claims description 3
• 241000710778 Pestivirus Species 0.000 claims description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
• 235000020958 biotin Nutrition 0.000 claims description 3
• 229960002685 biotin Drugs 0.000 claims description 3
• 239000011616 biotin Substances 0.000 claims description 3
• 210000004899 c-terminal region Anatomy 0.000 claims description 3
• 230000005764 inhibitory process Effects 0.000 claims description 3
• 238000007913 intrathecal administration Methods 0.000 claims description 3
• 108010031345 placental alkaline phosphatase Proteins 0.000 claims description 3
• 229920001282 polysaccharide Polymers 0.000 claims description 3
• 230000009529 traumatic brain injury Effects 0.000 claims description 3
• 241000700618 Vaccinia virus Species 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• 230000001131 transforming effect Effects 0.000 claims description 2
• 241000701447 unidentified baculovirus Species 0.000 claims description 2
• 102000001189 Cyclic Peptides Human genes 0.000 claims 5
• 108010069514 Cyclic Peptides Proteins 0.000 claims 5
• 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
• 241000713666 Lentivirus Species 0.000 claims 1
• 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
• 241000700584 Simplexvirus Species 0.000 claims 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 238000007911 parenteral administration Methods 0.000 claims 1
• 238000011200 topical administration Methods 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 description 82
• 102000004169 proteins and genes Human genes 0.000 description 59
• 235000001014 amino acid Nutrition 0.000 description 55
• 235000018102 proteins Nutrition 0.000 description 54
• 150000001413 amino acids Chemical class 0.000 description 52
• 229940024606 amino acid Drugs 0.000 description 51
• 210000001519 tissue Anatomy 0.000 description 44
• 241000699670 Mus sp. Species 0.000 description 42
• 101710100258 Plexin-A2 Proteins 0.000 description 37
• 102100034381 Plexin-A2 Human genes 0.000 description 35
• 210000004556 brain Anatomy 0.000 description 26
• 241001465754 Metazoa Species 0.000 description 25
• 241000699666 Mus <mouse, genus> Species 0.000 description 25
• 230000004927 fusion Effects 0.000 description 25
• 238000011282 treatment Methods 0.000 description 20
• 108020004414 DNA Proteins 0.000 description 19
• 102100034385 Plexin-A4 Human genes 0.000 description 18
• 239000003550 marker Substances 0.000 description 18
• 108010029485 Protein Isoforms Proteins 0.000 description 17
• 102000001708 Protein Isoforms Human genes 0.000 description 17
• 230000027455 binding Effects 0.000 description 17
• 108010076504 Protein Sorting Signals Proteins 0.000 description 16
• 101710100264 Plexin-A4 Proteins 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 14
• -1 ie. Proteins 0.000 description 14
• 238000000338 in vitro Methods 0.000 description 14
• 102000037865 fusion proteins Human genes 0.000 description 13
• 108020001507 fusion proteins Proteins 0.000 description 13
• 230000004048 modification Effects 0.000 description 13
• 238000012986 modification Methods 0.000 description 13
• 238000012544 monitoring process Methods 0.000 description 13
• 125000003729 nucleotide group Chemical group 0.000 description 13
• 230000001086 cytosolic effect Effects 0.000 description 12
• 238000012744 immunostaining Methods 0.000 description 12
• 230000028327 secretion Effects 0.000 description 12
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
• 108050003978 Semaphorin Proteins 0.000 description 11
• 102000014105 Semaphorin Human genes 0.000 description 11
• 125000003277 amino group Chemical group 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 239000002773 nucleotide Substances 0.000 description 11
• 230000006320 pegylation Effects 0.000 description 11
• 239000002953 phosphate buffered saline Substances 0.000 description 11
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 10
• DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 10
• 102000009203 Sema domains Human genes 0.000 description 10
• 108050000099 Sema domains Proteins 0.000 description 10
• 239000013060 biological fluid Substances 0.000 description 10
• 239000001963 growth medium Substances 0.000 description 10
• 238000009396 hybridization Methods 0.000 description 10
• 108020004999 messenger RNA Proteins 0.000 description 10
• 150000007523 nucleic acids Chemical group 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 108091006905 Human Serum Albumin Proteins 0.000 description 9
• 102000008100 Human Serum Albumin Human genes 0.000 description 9
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 9
• 102000047918 Myelin Basic Human genes 0.000 description 9
• 101710107068 Myelin basic protein Proteins 0.000 description 9
• 238000005917 acylation reaction Methods 0.000 description 9
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 9
• 238000005755 formation reaction Methods 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 102000039446 nucleic acids Human genes 0.000 description 9
• 108020004707 nucleic acids Proteins 0.000 description 9
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
• 238000009007 Diagnostic Kit Methods 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 230000037396 body weight Effects 0.000 description 8
• 230000021615 conjugation Effects 0.000 description 8
• 238000001514 detection method Methods 0.000 description 8
• 230000000694 effects Effects 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 239000007943 implant Substances 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 208000015122 neurodegenerative disease Diseases 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 7
• 208000028226 Krabbe disease Diseases 0.000 description 7
• 238000012217 deletion Methods 0.000 description 7
• 230000037430 deletion Effects 0.000 description 7
• 239000003814 drug Substances 0.000 description 7
• 238000007901 in situ hybridization Methods 0.000 description 7
• 235000002639 sodium chloride Nutrition 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 238000001262 western blot Methods 0.000 description 7
• 101710196304 Contactin-associated protein 1 Proteins 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 6
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
• 108020004566 Transfer RNA Proteins 0.000 description 6
• 229920004890 Triton X-100 Polymers 0.000 description 6
• 230000010933 acylation Effects 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 235000004279 alanine Nutrition 0.000 description 6
• 150000001299 aldehydes Chemical class 0.000 description 6
• 210000003050 axon Anatomy 0.000 description 6
• 230000003376 axonal effect Effects 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 230000008499 blood brain barrier function Effects 0.000 description 6
• 210000001218 blood-brain barrier Anatomy 0.000 description 6
• 125000004122 cyclic group Chemical group 0.000 description 6
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
• 239000003623 enhancer Substances 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 210000001328 optic nerve Anatomy 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 229920003023 plastic Polymers 0.000 description 6
• 239000004033 plastic Substances 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 125000003396 thiol group Chemical class [H]S* 0.000 description 6
• 101150095421 tig gene Proteins 0.000 description 6
• 229920003169 water-soluble polymer Polymers 0.000 description 6
• 108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 description 5
• 102100040458 2',3'-cyclic-nucleotide 3'-phosphodiesterase Human genes 0.000 description 5
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
• 241000283690 Bos taurus Species 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 241000283086 Equidae Species 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101001067178 Homo sapiens Plexin-A4 Proteins 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 239000013504 Triton X-100 Substances 0.000 description 5
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 150000001875 compounds Chemical class 0.000 description 5
• 210000000877 corpus callosum Anatomy 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 210000000653 nervous system Anatomy 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 238000006722 reduction reaction Methods 0.000 description 5
• 238000005932 reductive alkylation reaction Methods 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 210000004885 white matter Anatomy 0.000 description 5
• 241000251468 Actinopterygii Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 241000699800 Cricetinae Species 0.000 description 4
• 241000699802 Cricetulus griseus Species 0.000 description 4
• 241000938605 Crocodylia Species 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• 208000025966 Neurological disease Diseases 0.000 description 4
• 108700026244 Open Reading Frames Proteins 0.000 description 4
• 101710100263 Plexin A3 Proteins 0.000 description 4
• 102100034386 Plexin-A3 Human genes 0.000 description 4
• 108010022394 Threonine synthase Proteins 0.000 description 4
• 230000021736 acetylation Effects 0.000 description 4
• 238000006640 acetylation reaction Methods 0.000 description 4
• 238000005804 alkylation reaction Methods 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 238000001212 derivatisation Methods 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 235000019688 fish Nutrition 0.000 description 4
• 125000003827 glycol group Chemical group 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 230000006698 induction Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 230000035800 maturation Effects 0.000 description 4
• 238000002703 mutagenesis Methods 0.000 description 4
• 231100000350 mutagenesis Toxicity 0.000 description 4
• FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 4
• VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 230000006337 proteolytic cleavage Effects 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 239000004055 small Interfering RNA Substances 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 238000010798 ubiquitination Methods 0.000 description 4
• 230000034512 ubiquitination Effects 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 3
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 108010067770 Endopeptidase K Proteins 0.000 description 3
• 108700024394 Exon Proteins 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• FUSGACRLAFQQRL-UHFFFAOYSA-N N-Ethyl-N-nitrosourea Chemical compound CCN(N=O)C(N)=O FUSGACRLAFQQRL-UHFFFAOYSA-N 0.000 description 3
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 241000282887 Suidae Species 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• 230000001668 ameliorated effect Effects 0.000 description 3
• 230000009435 amidation Effects 0.000 description 3
• 238000007112 amidation reaction Methods 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 210000001130 astrocyte Anatomy 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000001638 cerebellum Anatomy 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• 239000007795 chemical reaction product Substances 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 229940104302 cytosine Drugs 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 102000004419 dihydrofolate reductase Human genes 0.000 description 3
• AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 230000022244 formylation Effects 0.000 description 3
• 238000006170 formylation reaction Methods 0.000 description 3
• 102000005396 glutamine synthetase Human genes 0.000 description 3
• 108020002326 glutamine synthetase Proteins 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000007917 intracranial administration Methods 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 208000036546 leukodystrophy Diseases 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 210000000274 microglia Anatomy 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 229920002451 polyvinyl alcohol Polymers 0.000 description 3
• 238000004393 prognosis Methods 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 230000002797 proteolythic effect Effects 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 210000003594 spinal ganglia Anatomy 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• SGNVTRHWJGTNKV-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 11-(2,5-dioxopyrrol-1-yl)undecanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCCCCCN1C(=O)C=CC1=O SGNVTRHWJGTNKV-UHFFFAOYSA-N 0.000 description 2
• TYKASZBHFXBROF-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(2,5-dioxopyrrol-1-yl)acetate Chemical compound O=C1CCC(=O)N1OC(=O)CN1C(=O)C=CC1=O TYKASZBHFXBROF-UHFFFAOYSA-N 0.000 description 2
• JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 2
• PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 2
• BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 2
• GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
• PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 2
• VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 2
• WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 2
• OWMCODAXNFNLCU-UHFFFAOYSA-N 2-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1=CN=CN1 OWMCODAXNFNLCU-UHFFFAOYSA-N 0.000 description 2
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
• 230000005730 ADP ribosylation Effects 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 102100033620 Calponin-1 Human genes 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 241000700198 Cavia Species 0.000 description 2
• 241000252203 Clupea harengus Species 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• 239000004971 Cross linker Substances 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 208000009889 Herpes Simplex Diseases 0.000 description 2
• 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
• 101001067187 Homo sapiens Plexin-A2 Proteins 0.000 description 2
• 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 108010025815 Kanamycin Kinase Proteins 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
• 108091092878 Microsatellite Proteins 0.000 description 2
• 101001067186 Mus musculus Plexin-A2 Proteins 0.000 description 2
• 101100030114 Mus musculus Plxna2 gene Proteins 0.000 description 2
• 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 2
• 102000055324 Myelin Proteolipid Human genes 0.000 description 2
• 206010029155 Nephropathy toxic Diseases 0.000 description 2
• 206010029400 Nicotinic acid deficiency Diseases 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 102000005803 Oligodendrocyte Transcription Factor 2 Human genes 0.000 description 2
• 108010019644 Oligodendrocyte Transcription Factor 2 Proteins 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241000282577 Pan troglodytes Species 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
• 108700031620 S-acetylthiorphan Proteins 0.000 description 2
• 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 102000007238 Transferrin Receptors Human genes 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 206010046865 Vaccinia virus infection Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 230000004520 agglutination Effects 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000010516 arginylation Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 238000006664 bond formation reaction Methods 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 244000309466 calf Species 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 150000001720 carbohydrates Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 230000017858 demethylation Effects 0.000 description 2
• 238000010520 demethylation reaction Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 235000013601 eggs Nutrition 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 150000002118 epoxides Chemical class 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
• 230000006251 gamma-carboxylation Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 229960002989 glutamic acid Drugs 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 239000010439 graphite Substances 0.000 description 2
• 229910002804 graphite Inorganic materials 0.000 description 2
• 150000003278 haem Chemical group 0.000 description 2
• 235000019514 herring Nutrition 0.000 description 2
• 208000010726 hind limb paralysis Diseases 0.000 description 2
• 102000044428 human PLXNA2 Human genes 0.000 description 2
• 102000051249 human Plxna4 Human genes 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 230000033444 hydroxylation Effects 0.000 description 2
• 238000005805 hydroxylation reaction Methods 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000026045 iodination Effects 0.000 description 2
• 238000006192 iodination reaction Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 230000007498 myristoylation Effects 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000000478 neocortex Anatomy 0.000 description 2
• 230000007694 nephrotoxicity Effects 0.000 description 2
• 231100000417 nephrotoxicity Toxicity 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 238000002135 phase contrast microscopy Methods 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000013600 plasmid vector Substances 0.000 description 2
• 108050009312 plexin Proteins 0.000 description 2
• 102000002022 plexin Human genes 0.000 description 2
• 108010055896 polyornithine Proteins 0.000 description 2
• 229920002714 polyornithine Polymers 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000013823 prenylation Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000009145 protein modification Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
• 229940043131 pyroglutamate Drugs 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 230000006340 racemization Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000007363 ring formation reaction Methods 0.000 description 2
• 238000007873 sieving Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
• 230000019635 sulfation Effects 0.000 description 2
• 238000005670 sulfation reaction Methods 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 208000007089 vaccinia Diseases 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
• AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
• 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• BTBWSRPRAGXJJV-UHFFFAOYSA-N 2h-benzotriazole;carbonic acid Chemical class OC(O)=O.C1=CC=C2NN=NC2=C1 BTBWSRPRAGXJJV-UHFFFAOYSA-N 0.000 description 1
• QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 239000013607 AAV vector Substances 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 1
• 241000282421 Canidae Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 238000011537 Coomassie blue staining Methods 0.000 description 1
• 241000252212 Danio rerio Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 101150005585 E3 gene Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 108010088842 Fibrinolysin Proteins 0.000 description 1
• 241000282818 Giraffidae Species 0.000 description 1
• 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
• 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
• 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101001067176 Mus musculus Plexin-A4 Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 108700021862 Myelin Proteolipid Proteins 0.000 description 1
• 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 241001045988 Neogene Species 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 241000282376 Panthera tigris Species 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000002141 Pellagra Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 241000282405 Pongo abelii Species 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 239000005700 Putrescine Substances 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 102000013008 Semaphorin-3A Human genes 0.000 description 1
• 108010090319 Semaphorin-3A Proteins 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 241000251778 Squalus acanthias Species 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 150000001294 alanine derivatives Chemical class 0.000 description 1
• 125000003172 aldehyde group Chemical group 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000004009 axon guidance Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 238000002725 brachytherapy Methods 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 230000031736 central nervous system myelination Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 239000012501 chromatography medium Substances 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 229920000547 conjugated polymer Polymers 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 229940068840 d-biotin Drugs 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 230000002542 deteriorative effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000009088 enzymatic function Effects 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229940047127 fiore Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000003197 gene knockdown Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 230000024924 glomerular filtration Effects 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 102000047882 human INSR Human genes 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000014726 immortalization of host cell Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000000951 immunodiffusion Effects 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229950008325 levothyroxine Drugs 0.000 description 1
• 208000027905 limb weakness Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 208000018883 loss of balance Diseases 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 238000009593 lumbar puncture Methods 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000002052 molecular layer Substances 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 101150091879 neo gene Proteins 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000003715 nutritional status Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 210000005059 placental tissue Anatomy 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000007542 postnatal development Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 210000004129 prosencephalon Anatomy 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 235000008160 pyridoxine Nutrition 0.000 description 1
• 239000011677 pyridoxine Substances 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000005185 salting out Methods 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000010008 shearing Methods 0.000 description 1
• 239000013605 shuttle vector Substances 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229940035722 triiodothyronine Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 108010087967 type I signal peptidase Proteins 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 229940011671 vitamin b6 Drugs 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1